MagForce AG is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
Initial listing
20.09.2007
Accounting standards
German Commercial Code ("HGB")
Fiscal year end
December 31
Executive Board
Dr. Ben J. Lipps, Christian von Volkmann
Supervisory Board
Norbert Neef (Chairman), Klemens Hallmann, Aron Weaver
Registered Office
Max-Planck-Str 3, 12489 Berlin, Germany
ISIN
DE000A0HGQF5
Stock Exchange
Xetra/Frankfurt
German Securities Identification Number (WKN)
A0HGQF
Ticker Symbol
MF6
Market Segment
Scale
Stock Class
No-par-value shares
Share Capital
27,640,274 Euro
Total Number of Shares
27,640,274 shares
Specialist
Steubing AG
Applying & Supervising Capital Markets Partner, Designated Sponsor
Hauck & Aufhäuser